The oral prodrug fostamatinib (active metabolite, R406) is a first-in-class Syk inhibitor approved in the United States for the treatment of immune thrombocytopenia (ITP) [21]. The gene discussed is SYK; the disease is autoimmune thrombocytopenic purpura.